|
1
|
Albelda SM, Mette SA, Elder DE, Stewart R,
Damjanovich L, Herlyn M and Buck CA: Integrin distribution in
malignant melanoma: association of the β3 subunit with tumor
progression. Cancer Res. 50:6757–6764. 1990.
|
|
2
|
Hieken TJ, Farolan M, Ronan SG, Shilkaitis
A, Wild L and Das Gupta TK: β3 integrin expression in melanoma
predicts subsequent metastasis. J Surg Res. 63:169–173. 1996.
|
|
3
|
Trikha M, Timar J, Zacharek A, Nemeth JA,
Cai Y, Dome B, Somlai B, Raso E, Ladanyi A and Honn KV: Role for β3
integrins in human melanoma growth and survival. Int J Cancer.
101:156–167. 2002.
|
|
4
|
Cooper CR, Chay CH and Pienta KJ: The Role
of alpha(v)beta(3) in prostate cancer progression. Neolplasia.
4:191–194. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rezaeipoor R, Chaney EJ, Oldenburg AL and
Boopart S: Expression order of alpha-v and beta-3 integrin subunits
in the N-methyl-N-nitrosourea-induced rat mammary tumor model.
Cancer Invest. 27:496–503. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leu SJ, Lam SC and Lau LF: Pro-angiogenic
activities of CYR61 (CCN1) mediated through integrins avb3 and a6b1
in human umbilical vein endothelial cells. J Biol Chem.
277:46248–46255. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nam JO, Kim JE, Jeong HW, Lee SJ, Lee BH,
Choi JY, Park RW, Park JY and Kim IS: Identification of the αvβ3
integrin-interacting motif of βig-h3 and its anti-angiogenic
effect. J Biol Chem. 278:25902–25909. 2003.
|
|
8
|
Mizejewski GJ: Role of integrins in
cancer: survey of expression patterns. Proc Soc Exp Biol Med.
222:124–138. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Minamiguchi K, Kumagai H, Masuda T, Kawada
M, Ishizuka M and Takeuchi T: Thiolutin, an inhibitor of HUVEC
adhesion to vitronectin, reduces paxillin in HUVECs and suppresses
tumour cell-induced angiogenesis. Int J Cancer. 93:307–316. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nikos E, Tsopanoglou NE, Andriopoulou P
and Maragoudakis ME: On the mechanism of thrombin-induced
angiogenesis: involvement of αvβ3-integrin. Am J Physiol Cell
Physiol. 283:1501–1510. 2002.PubMed/NCBI
|
|
11
|
Burns GF, Cosgrove L, Triglia T, Beall JA,
Lopez AF, Werkmeister JA, Begley CG, Haddad AP, d’Apice AJ, Vadas
MA, et al: The IIb-IIIa glycoprotein complex that mediates platelet
aggregation is directly implicated in leukocyte adhesion. Cell.
45:269–280. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Timar J, Trikha M, Szekeres K, Bazaz R,
Tovari J, Silletti S, Raz A and Honn KV: Autocrine motility factor
signals integrin-mediated metastatic melanoma cell adhesion and
invasion. Cancer Res. 56:1902–1908. 1996.PubMed/NCBI
|
|
13
|
Oleksowicz L, Mrowiec Z, Schwartz E,
Khorshidi M, Dutcher J and Puszkin E: Characterization of
tumour-induced platelet aggregation: the role of immunorelated GPIb
and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thromb Res.
79:261–274. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sheu JR, Lin CH, Peng HC and Huang TF:
Triflavin, an Arg-Gly-Asp-containing peptide, inhibits human
cervical carcinoma (HeLa) cell-substratum adhesion through an
RGD-dependent mechanism. Peptides. 15:1391–1398. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yun Z, Menter DG and Nicolson GL:
Involvement of integrin alphavbeta3 in cell adhesion, motility, and
liver metastasis of murine RAW117 large cell lymphoma. Cancer Res.
56:3103–3111. 1996.PubMed/NCBI
|
|
16
|
Cohen SA, Trikha M and Mascelli MA:
Potential future clinical applications for the GPIIb/IIIa
antagonist, abciximab in thrombosis, vascular and oncological
indications. Pathol Oncol Res. 6:163–174. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Auzzas L, Zanardi F, Battistini L,
Burreddu P, Carta P, Rassu G, Curti C and Casiraghi G: Targeting
alphavbeta3 integrin: design and applications of mono- and
multifunctional RGD-based peptides and semipeptides. Curr Med Chem.
17:1255–1299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Skehan P, Storeng R, Sudiero D, Monks A,
McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR:
New colorimetric cytotoxicity assay for anticancer-drug screening.
J Natl Cancer Inst. 82:1107–1112. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang YS, Chen YQ, Timar J, Nelson KK,
Grossi IM, Fitzgerald LA, Diglio CA and Honn KV: Increased
expression of alpha IIb beta 3 integrin in subpopulations of murine
melanoma cells with high lung-colonizing ability. Int J Cancer.
51:445–451. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Van Belle PA, Elenitsas R, Satyamoorthy K,
Wolfe JT, Guerry DI, Schuchter L, Van Belle TJ, Albelda S, Tahin P,
Herlyn M and Elder DE: Progression-related expression of beta3
integrin in melanomas and nevi. Hum Pathol. 33:562–567.
1999.PubMed/NCBI
|
|
21
|
Perdih A and Dolenc MS: Small molecule
antagonists of integrin receptors. Curr Med Chem. 17:2371–2392.
2010. View Article : Google Scholar
|
|
22
|
Brooks PC, Stromblad S, Klemke R, Visscher
D, Sarkar FH and Cheresh DA: Antiintegrin alpha v beta 3 blocks
human breast cancer growth and angiogenesis in human skin. J Clin
Invest. 96:1815–1822. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mitjans F, Meyer T, Fittschen C, Goodman
S, Jonczyk A, Marshall JF, Reyes G and Piulats J: In vivo therapy
of malignant melanoma by means of antagonists of αv integrins. Int
J Cancer. 87:716–723. 2000.
|
|
24
|
Isoai A, Ueno Y, Giga-Hama Y, Goto H and
Kumagai HA: A novel Arg-Gly-Asp containing peptide specific for
platelet aggregation and its effect on tumor metastasis: a possible
mechanism of RGD peptide-mediated inhibition of tumor metastasis.
Cancer Lett. 65:259–264. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Buerkle MA, Pahernik SA, Sutter A, Jonczyk
AKM and Dellian M: Inhibition of the alpha-nu integrins with a
cyclic RGD peptide impairs angiogenesis, growth and metastasis of
solid tumours in vivo. Br J Cancer. 86:788–795. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Perkins JJ, Duong LT, Fernandez-Metzler C,
Hartman GD, Kimmel DB, Leu C-T, Lynch JJ, Prueksaritanont T, Rodan
GA, Rodan SB, et al: Non-peptide alpha(v)beta(3) antagonists:
identification of potent, chain-shortened RGD mimetics that
incorporate a central pyrrolidinone constraint. Bioorg Med Chem
Lett. 13:4285–4288. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han HD, Mangala LS, Lee JW, Shahzad MM,
Kim HS, Shen D, Nam EJ, Mora EM, Stone RL, Lu C, et al: Targeted
gene silencing using RGD-labeled chitosan nanoparticles. Clin
Cancer Res. 16:3910–3922. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Roman J, Ritzenthaler JD, Roser-Page S,
Sunx and Han S: Alpha5beta1-integrin expression is essential for
tumor progression in experimental lung cancer. Am J Respir Cell Mol
Biol. 43:684–691. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fire A, Xu S, Montgomery MK, Kostas SA,
Driver SE and Mello CC: Potent and specific genetic interference by
double-stranded RNA in Caenorhabditis elegans. Nature.
391:806–811. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Castanotto D and Rossi JJ: The promises
and pitfalls of RNA-interference-based therapeutics. Nature.
457:426–433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hart IR, Birch M and Marshall JF: Cell
adhesion receptor expression during melanoma progression and
metastasis. Cancer Metastasis Rev. 10:115–128. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Seftor RE: Role of the beta3 integrin
subunit in human primary melanoma progression: multifunctional
activities associated with alpha(v)beta3 integrin expression. Am J
Pathol. 153:1347–1351. 1998. View Article : Google Scholar
|
|
33
|
Switala-Jelen K, Dabrowska K, Opolski A,
Lipinska L, Nowaczyk M and Gorski A: The biological functions of
beta3 integrins. Folia Biol. 50:143–152. 2004.PubMed/NCBI
|
|
34
|
Akiyama SK, Olden K and Yamada KM:
Fibronectin and integrins in invasion and metastsis. Cancer
Metastasis Rev. 14:173–189. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Palumbo JS, Kombrinck KW, Drew AF, Grimes
TS, Kiser JH, Degen JL and Bugge TH: Fibrinogen is an important
determinant of the metastatic potential of circulating tumor cells.
Blood. 96:3302–3309. 2000.PubMed/NCBI
|
|
36
|
Yi M and Ruoslahti E: A fibronectin
fragment inhibits tumor growth, angiogenesis and metastasis. Proc
Natl Acad Sci USA. 98:620–624. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gong W, Liu Y, Huang B, Lei Z, Wu F-H, Li
D, Feng Z-H and Zhang G-M: Recombinant CBD-HepII polypeptide of
fibronectin inhibits αvβ3 signaling and hematogenous metastasis of
tumor. Biochem Biophys Res Commun. 367:144–149. 2008.
|
|
38
|
Ramos OH, Kauskot A, Cominetti MR, Bechyne
I, Salla Pontes CL, Chareyre F, Manent J, Vassy R, Giovannini M,
Legrand C, et al: A novel avb3-blocking disintegrin containing the
RGD motive DisBa-01, inhibits bFGF-induced angiogenesis and
melanoma metastasis. Clin Exp Metastasis. 25:53–64. 2008.
View Article : Google Scholar
|
|
39
|
Sheldrake HM and Patterson LH: Function
and antagonism of beta3 integrins in the development of cancer
therapy. Curr Cancer Drug Targets. 9:519–540. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gehlsen KR, Davis GE and Sriramarao P:
Integrin expression in human melanoma cells with differing invasive
and metastatic properties. Clin Exp Metastasis. 10:111–120. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rebhun RB, Cheng H, Gershenwald JE, Fan D,
Fidler IJ and Langley RR: Constitutive expression of the alpha4
integrin correlates with tumorigenicity and lymph node metastasis
of the B16 murine melanoma. Neoplasia. 12:173–182. 2010.PubMed/NCBI
|
|
42
|
Zheng S, Shen J, Jiao Y, Zhang C, Wei M,
Hao S and Zeng X: Platelets and fibrinogen facilitate each other in
protecting tumor cells from natural killer cytotoxicity. Cancer
Sci. 100:859–865. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cavanaugh PG, Sloane BF and Honn KV: Role
of the coagulation system in tumor-cell-induced platelet
aggregation and metastasis. Haemostasis. 18:37–46. 1988.PubMed/NCBI
|
|
44
|
Crissman JD, Hatfield JS, Menter DG,
Sloane B and Honn KV: Morphological study of the interaction of
intravascular tumor cells with endothelial cells and subendothelial
matrix. Cancer Res. 48:4065–4072. 1988.PubMed/NCBI
|
|
45
|
Liu Y, Zhao F, Gu W, Yang H, Meng Q, Zhang
Y, Yang H and Duan Q: The roles of platelet GPIIb/IIIa and
alphavbeta3 integrins during HeLa cells adhesion, migration, and
invasion to monolayer endothelium under static and dynamic shear
flow. J Biomed Biotechnol. 2009:8292432009.PubMed/NCBI
|
|
46
|
Ria R, Vacca A, Ribatti D, Di Raimondo F,
Merchionne F and Dammacco F: Alpha(v)beta(3) integrin engagement
enhances cell invasiveness in human multiple myeloma.
Haematologica. 87:836–845. 2002.PubMed/NCBI
|
|
47
|
Sato T, Sakai T, Noguchi Y, Takita M,
Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion
of human uterine cervical carcinoma cells by augmenting the
expression and activation of stromal matrix metalloproteinases.
Gynecol Oncol. 92:47–56. 2004. View Article : Google Scholar
|
|
48
|
Cary LA and Guan JL: Focal adhesion kinase
in integrin-mediated signaling. Front Biosci. 4:D102–D113. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hao H, Naomoto Y, Bao X, Watanabe N,
Sakurama K, Noma K, Motoki T, Tomono Y, Fukazawa T, Shirakawa Y, et
al: Focal adhesion kinase as potential target for cancer therapy
(Review). Oncol Rep. 22:973–979. 2009.PubMed/NCBI
|
|
50
|
Yang J, Price MA, Li GY, Bar-Eli M, Salgia
R, Jagedeeswaran R, Carlson JH, Ferrone S, Turley EA and McCarthy
JB: Melanoma proteoglycan modifies gene expression to stimulate
tumor cell motility, growth, and epithelial-to-mesenchymal
transition. Cancer Res. 69:7538–7547. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hou CH, Yang RS, Hou SM and Tang CH: TNF-α
increases αvβ3 integrin expression and migration in human
chondrosarcoma cells. J Cell Physiol. 226:792–799. 2011.
|
